Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

US9273135B2 · kind B2 · utility

Assignee

• E.R. SQUIBB & SONS, L.L.C. · US

Inventors

• Alan J. Korman · Piedmont, US
• Mark J. Selby · San Francisco, US
• Changyu Wang · Union City, US
• Mohan Srinivasan · Cupertino, US
• David B. Passmore · Mountain View, US
• Haichun Huang · Fremont, US
• Haibin Chen · Ningbo City, CN

Key dates

• Filing date: Jul 10, 2015
• Grant date: Mar 1, 2016
• Expiry date: Jul 10, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-LI antibodies.